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 There have been concerns about 
the accuracy of the Modification of 
Diet in Renal Disease (MDRD) formula 
in the normal range and in the upper 
range of stage 3 chronic kidney disease 
(CKD). Do all of the individuals diag-
nosed with stage 3 CKD actually have 
CKD? Only some with eGFR in the 60 –
 90  ml / min per 1.73  m 2 range have decre-
ments in GFR and are at risk for 
progression, but it is di3  cult to identify 
these individuals. These cases may 
be a situation in which cystatin C would 
be particularly useful. What is needed is 
a study of measurement of GFR in the 
general population with simultaneous 
measurement of creatinine and cystatin 
C, an area that has not been a high prior-
ity in large epidemiologic studies (Figure 
1a). In addition, we need a study that 
evaluates GFR in the general medical 
population, particularly the elderly, 
where loss of lean mass that affects 
creatinine values may be particularly 
relevant (Figure 1b). 
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 In the general population, a strong asso-
ciation between low bone mineral density 
or osteoporosis and vascular calci cation 
exists. Apparently, demineralization of 
the bone goes along with the formation 
of a bone-like structure in the arteries, 
which is called the calci cation paradox. 
The link between artery calcification 
and bone diseases is also reported in 
patients with chronic kidney disease 
(CKD). Both high- and low-turnover 
bone disease, manifested as hyperpar-
athyroid and adynamic bone, respectively, 
may contribute to the onset and / or pro-
gression of arterial calci cation in renal 
failure patients. High bone formation and 
resorption rates represent an increased 
exchange of calcium and phosphate 
between the serum and the bone com-
partments. The continuous supply of 
these substrates from the bone to the 
serum can be responsible for the close 
association between high bone turnover 
and vascular calci cation. On the other 
hand, in the case of adynamic bone dis-
ease, inactive bone remodeling leads to 
an impaired capacity of the bone to bu8 er 
circulating calcium and phosphate, result-
ing in a decreased rate of incorporation 
of calcium and phosphate into the bone, 
which ultimately augments the risk for 
extraosseous calci cation. 
 In CKD patients, the prevalence of 
osteoporosis is high and bone mineral 
density decreases gradually with declin-
ing renal function. 1 Osteoporosis may 
coexist with either high bone turnover or 
low bone turnover. However, the mecha-
nisms that may explain the concomitant 
appearance of a decreased bone mineral 
density and calci ed areas in the vessel 
wall are still poorly understood. Potential 
mechanisms for this paradox are pre-
sented in  Figure 1 . 
 In CKD patients, inflammatory 
markers such as tumor necrosis factor-  
and interleukin-6 as well as lipids, 
particularly oxidized low-density lipo-
protein, are proposed to be responsible 
for the interaction between bone loss 
and vascular calcification by exerting 
adverse actions in the bone and the vessel 
wall. Oxidized lipids promote osteogenic 
differentiation and mineralization of 
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 Arterial calcification has been found to coexist with bone loss. 
Bisphosphonates, used as standard therapy for osteoporosis, inhibit 
experimentally induced vascular calcification, offering perspectives for 
the treatment of vascular calcification in renal failure patients. 
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vascular cells, 2 while they reduce bone 
mineralization. 3 Furthermore, the 
osteoprotegerin – RANK – RANKL triad 
may play a role in the calci cation para-
dox. Osteoprotegerin (OPG) knockout 
mice exhibit a combination of osteoporo-
sis and media calcifications in the 
aorta, 4 suggesting that OPG, an inhibitor 
of bone resorption, has a dual effect 
on bone and arteries, as it reduces 
bone resorption and inhibits artery 
calci cation. 
 An increased bone resorption itself is 
also recognized as a causal factor for the 
relationship between osteoporosis and 
arterial calci cation. Evidence is provided 
by studies showing that treatment with 
di8 erent types of bone resorption inhibi-
tors, each with a di8 erent mode of action 
on the osteoclast, prevents the develop-
ment of vascular calci cation. Adminis-
tration of a V-H   +   -ATPase inhibitor, 5 an 
enzyme required for proton secretion by 
osteoclasts to acidify and dissolve bone 
mineral, as well as OPG treatment 6 pre-
vented vitamin D-induced arterial calci -
cation in rats. Bisphosphonates also 
reduced the development of experimen-
tally induced media calci cation in rats 
with chronic renal failure. These non-
hydrolyzable pyrophosphate analogues 
inhibit osteoclast di8 erentiation, recruit-
ment, and activity and are prescribed 
worldwide for the treatment of osteoporo-
sis. First-class non-nitrogen-containing 
bisphosphonates such as etidronate are 
metabolized into compounds that com-
pete with ATP in the cellular energy 
metabolism, thereby inducing osteoclast 
apoptosis. Newer nitrogenous bisphos-
phonates inhibit the intracellular target 
enzyme farnesyl pyrophosphate synthase. 
' is enzyme is involved in the synthesis 
of small G proteins that are essential for 
the control of several cellular processes, 
such as signal transduction, organization 
of the cytoskeleton, and cellular protein 
tra3  c. Price and co-workers found that 
alendronate and ibandronate inhibit 
artery calci cation in rats with warfarin-
induced vascular calci cation and rats 
with uremia-induced media calci cation 
at doses that inhibit bone resorption. 7,8 
' ese reports have prompted the growing 
interest in bisphosphonates as a treatment 
strategy in the prevention of arterial 
calcification. Studies investigating the 
effect of bisphosphonates on both the 
bone turnover and the calci cation proc-
esses in the vessel wall were lacking. ' ey 
are, however, highly needed, particularly 
in patients with advanced CKD, in view 
of their severe bone and mineral distur-
bances. Lomashvili  et al. 9 (this issue) 
report that etidronate and pamidronate 
indeed prevent the development of 
vascular calcification in rats with 
adenine-induced chronic renal failure, 
but at the same time bone formation 
and mineralization are a8 ected. ' ese 
findings extend previous results of 
Tamura  et al. 10 showing that the most 
e8 ective etidronate dose for the preven-
tion of arterial calci cation reduced bone 
mineral density in 5/6-nephrectomized 
rats. Both studies suggest that inhibition 
of arterial calci cation by bisphospho-
nates holds a risk for bone metabolism 
and that prevention of vessel calci cation 
can thus far not be established without 
a8 ecting the bone. 
 ' e exact mechanism by which bisphos-
phonates inhibit artery calci cation is not 
entirely understood. One possibility is an 
indirect e8 ect through inhibition of bone 
resorption, which reduces the eP  ux of 
calcium and phosphate out of the bone, 
resulting in a decreased availability of the 
substrates required to form hydroxyapa-
tite in the arterial wall. This is rather 
unlikely, as various studies did not  nd a 
decrease in serum calcium and phosphate 
levels following bisphosphonate adminis-
tration. Moreover, the study by Lomashvili 
 et al. 9 reports that the prevention of vas-
cular calci cation was associated not with 
an inhibition of bone resorption, but, 
rather unexpectedly, with the inhibition 
of bone formation . Alternatively, bisphos-
phonates may exert a direct e8 ect on the 
vascular wall, either physicochemically 
through interference with the mineral for-
mation or biologically at the cellular level 
through modulation of the transdi8 eren-
tiation of vascular smooth muscle cells 
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 Figure 1  |  Potential mechanisms involved in the calcification paradox. Bisphosphonates may reduce vascular calcification indirectly by inhibiting 
bone resorption or directly by either physicochemical interference with hydroxyapatite crystal formation or biological interaction with vascular 
smooth muscle cell function in the vessel wall. LDL, low-density lipoprotein. 
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into an osteoblast-like phenotype, which 
is a well-known mechanism underlying 
the calcification process in the artery. 
Interestingly, Lomashvili  et al. 9 for the  rst 
time examine the isolated effect of 
bisphosphonates on the development of 
calci cation in rat aorta cultures. Etidro-
nate and pamidronate significantly 
reduced the calcium content in aortae 
cultured in medium containing alkaline 
phosphatase and warfarin to induce 
calci cation, as well as in injured aortae . 
Additionally, etidronate prevented 
further progression of manifested calci-
fied areas but could not reverse the 
calci cation process. No e8 ect of etidro-
nate was found on the expression of oste-
ogenic markers in calcifying cultured 
aortae, indicating that bisphosphonates 
do not inJ uence osteogenic transdi8 eren-
tiation of vascular smooth muscle 
cells. Taken together, these results 
strongly support the hypothesis that 
bisphosphonates prevent arterial calci -
cation by blocking the physicochemical 
formation of apatite crystals in the 
vessel as they do in the bone of the 
rat model of Lomashvili  et al. 9 This is 
not surprising given the structural 
resemblance of these agents to the calci -
cation inhibitor pyrophosphate. Yet, as 
bisphosphonates a8 ect cellular functions, 
cellular alterations involved in the inhi-
bition of vascular calcification cannot 
be excluded. Possibly, bisphosphonates 
may interfere with the formation or 
transport of matrix vesicles loaded 
with nascent apatite crystals in osteoblast-
like cells in the vessel wall, thereby pre-
venting the development of arterial 
calci cation. 
 The report by Lomashvili  et al. 9 
indicates that caution is strongly advised 
for the use of bisphosphonates to treat 
vascular calcification, especially in 
patients with CKD, who su8 er from an 
impaired bone turnover inherent to 
the underlying disease state. As shown, 
these agents can cause impaired bone 
mineralization, which eventually may 
lead to osteomalacia as a consequence 
of prolonged administration. Moreover, 
by a8 ecting bone formation, bisphospho-
nate use may completely block bone 
turnover,  ultimately aggravating 
adynamic bone, which in turn has been 
considered a risk factor for vascular 
calci cation. 
 Despite the relevant contribution of 
Lomashvili  et al. 9 to the elucidation of the 
mechanisms by which bisphosphonates 
prevent artery calci cation, some issues 
should be taken into account and require 
further examination. Primarily, etidronate 
and pamidronate have a relatively low 
potency regarding the inhibition of bone 
resorption. High doses are required to 
exert their inhibitory action on the osteo-
clast, which simultaneously causes inhibi-
tion of hydroxyapatite formation in the 
bone. Newer bisphosphonates such 
as risedronate and zoledronate, with a 
1000- to 10,000-times-greater potency 
than etidronate, are used at lower doses 
and will less likely reduce bone minerali-
zation. ' erefore, it is important to inves-
tigate whether administration of more 
potent bisphosphonates can inhibit 
vascular calci cation without reducing 
bone mineralization. In addition, to deter-
mine whether or not bone resorption itself 
is related to crystal formation in the arter-
ies, the e8 ect of bisphosphonates on bone 
and arteries should be examined in an 
animal model with increased bone resorp-
tion and apparent bone loss and with con-
comitant development of vascular 
calcification — for example, the OPG 
knockout mouse model. In contrast to the 
uremic rat model with only slightly 
increased bone resorption parameters that 
was used by Lomashvili  et al. , 9 bisphos-
phonates will have the opportunity to 
exert their antiresorbing e8 ect in an oste-
oporotic animal model. 
 ' e therapeutic use of bisphosphonates 
in CKD patients should be carefully eval-
uated. Although bisphosphonate treat-
ment was studied in renal-transplant 
patients, a population at high risk for rapid 
bone loss, the lack of pharmacokinetic 
studies in end-stage renal failure patients 
precludes the use of these drugs in the lat-
ter population. A signi cant proportion 
of these patients shows low bone turnover. 
It is not inconceivable that bisphospho-
nates aggravate adynamic bone disease 
and thus increase the risk for arterial cal-
ci cation. ' erefore, the e8 ect of bisphos-
phonates on adynamic bone and its 
coexistence with vascular calcification 
need to be investigated. Relatively small 
clinical studies showed that etidronate 
stopped the progression of coronary and 
aortic calcification in hemodialysis 
patients. 11,12 However, perspectives con-
cerning a therapeutic window for bisphos-
phonates in the treatment of artery 
calci cation will mainly depend on their 
action on bone resorption as well as on 
bone formation, particularly in CKD 
patients with underlying renal osteodys-
trophy, covering a wide range of abnormal 
bone turnover rates. 
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